RESUMO
No disponible
Assuntos
Humanos , Masculino , Angioedema/epidemiologia , Angioedema/etiologia , Anti-Inflamatórios não Esteroides/efeitos adversos , Hipersensibilidade a Drogas/epidemiologia , Hipersensibilidade a Drogas/etiologia , Biomarcadores/sangue , Brasil/epidemiologia , Suscetibilidade a Doenças , Estudos de Associação Genética/métodos , Predisposição Genética para Doença , Mutação , Vigilância da População , Sequenciamento do ExomaRESUMO
No disponible
Assuntos
Humanos , Feminino , Gravidez , Adulto , Urticária/induzido quimicamente , Urticária/complicações , Complicações na Gravidez/tratamento farmacológico , Omalizumab/administração & dosagem , Urticária/tratamento farmacológico , Prurido/induzido quimicamente , Prurido/complicações , Angioedema/induzido quimicamente , Angioedema/complicações , Anticorpos Antinucleares/análise , Hipersensibilidade Imediata/complicações , Imunoglobulina E/análiseRESUMO
This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2) LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The life-time prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).
Assuntos
Humanos , Urticária , Urticária/diagnóstico , Urticária/terapiaRESUMO
This methods report describes the process of guideline development in detail. It is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2) LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS) and is published in Allergy 2014; 69:868-887
